Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 plus anticancer agents in advanced solid tumors (IB/II, KRAS G12D)
CTR20242710Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Aug 2024; status: active.
02
Drugs
HRS-4642
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242710.